Literature DB >> 8866772

Motor and mental aspects of extrapyramidal syndromes.

D E Casey1.   

Abstract

Neuroleptic-induced extrapyramidal syndromes (EPS) are major limitations to effective antipsychotic therapy. There are both motor (objective) and mental (subjective) components to EPS, which must be considered in the evaluation and differential diagnosis of treatment-related adverse events. In addition to causing motor impairment, these syndromes can also produce irritability, anxiousness and secondary negative symptoms of slow thinking and emotional blunting. The EPS of akathisia, dystonia, and parkinsonism have unique characteristics that are influenced by patient, drug and temporal aspects. With the advent of new and novel antipsychotic drugs that have low EPS liability, patients will have fewer side effects, be less non-compliant and more able to benefit from rehabilitation efforts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8866772

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  10 in total

1.  Atypical antipsychotics.

Authors:  S Kapur; G Remington
Journal:  BMJ       Date:  2000-12-02

2.  Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

Authors:  Rajiv Tandon
Journal:  Psychiatr Q       Date:  2002

3.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

4.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

5.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen; Yuki Takahashi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

Review 6.  Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

Authors:  Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.

Authors:  Raquel Cristine Silva Barcelos; Dalila Moter Benvegnú; Nardeli Boufleur; Patrícia Reckziegel; Liz Girardi Müller; Camila Pase; Tatiana Emanuelli; Marilise Escobar Bürger
Journal:  Neurotox Res       Date:  2009-07-31       Impact factor: 3.911

Review 8.  Quantitative analysis of motor disturbances in schizophrenic patients.

Authors:  Albert Putzhammer; Helmfried E Klein
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

9.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-28       Impact factor: 2.570

Review 10.  Second-generation antipsychotics and extrapyramidal adverse effects.

Authors:  Nevena Divac; Milica Prostran; Igor Jakovcevski; Natasa Cerovac
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.